INS and type 2 diabetes mellitus: In a similar randomized controlled trial, Heise et al. examined 117 patients diagnosed with T2DM for at least six months who were administered either 15 mg subcutaneous tirzepatide, 1 mg subcutaneous semaglutide, or a placebo for 28 weeks to assess HbA1c and fasting insulin [22]. HbA1c in the tirzepatide group improved by 22 mmol after 28 weeks, compared to 17.9 mmol in the semaglutide group [22].